Interestingly, there was a 2.5-fold decrease in the percentage of CD16+CD56+ cells (P = 0.0006; Figure 2C) in the progressors at follow-up (blood was obtained when they developed active TB) compared with the baseline values. The gene discussed is NCAM1; the disease is tuberculosis.